We are live on ! Find out more
AGP

Artia Global Partners Portfolio holdings

AUM $542M
1-Year Est. Return 206.64%
This Fund
S&P 500
This Quarter Est. Return
+28.45%
1 Year Est. Return
+206.64%
3 Year Est. Return
+724.84%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$542M
AUM Growth
+$42.4M
Cap. Flow
+$30.9M
Cap. Flow %
5.7%
Top 10 Hldgs %
64.55%
Holding
57
New
7
Increased
11
Reduced
3
Closed
9

Top Buys

Rank Stock Value
1
BTSG icon
BrightSpring Health Services
BTSG
+$25.7M
2
ALKS icon
Alkermes
ALKS
+$17.5M
3
TVTX icon
Travere Therapeutics
TVTX
+$11.9M
4
RVMD icon
Revolution Medicines
RVMD
+$8.82M
5
CELC icon
Celcuity
CELC
+$5.05M

Top Sells

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$35.2M
2
ABVX
Abivax
ABVX
+$9.54M
3
TERN
Terns Pharmaceuticals
TERN
+$5.53M
4
INSM icon
Insmed
INSM
+$4.8M
5
ABBV icon
AbbVie
ABBV
+$3.15M

Sector Composition

Rank Sector Weight
1 Healthcare 97.08%
2 Miscellaneous 2.92%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ABVX
1
Abivax
ABVX
$10.4B
$68.8M 12.7%
516,447
-84,300
-14% -$9.54M
INSM icon
2
Insmed
INSM
$27.6B
$62.8M 11.59%
589,052
-39,660
-6% -$4.8M
TRVI icon
3
Trevi Therapeutics
TRVI
$2.39B
$41.2M 7.61%
2,210,852
+197,250
+10% +$2.87M
BTSG icon
4
BrightSpring Health Services
BTSG
$12.2B
$36.1M 6.66%
517,315
+463,515
+862% +$25.7M
RVMD icon
5
Revolution Medicines
RVMD
$44.7B
$34.7M 6.41%
185,390
+60,400
+48% +$8.82M
ARGX icon
6
argenx
ARGX
$62.4B
$27.6M 5.09%
29,739
– –
ALKS icon
7
Alkermes
ALKS
$7.58B
$23.5M 4.34%
+448,964
New +$17.5M
TVTX icon
8
Travere Therapeutics
TVTX
$6.33B
$19.3M 3.55%
339,033
+268,333
+380% +$11.9M
AZN icon
9
AstraZeneca
AZN
$246B
$18.7M 3.44%
98,376
+3,000
+3% +$564K
NAMS icon
10
NewAmsterdam Pharma
NAMS
$3.01B
$17.1M 3.15%
503,936
– –
DNTH icon
11
Dianthus Therapeutics
DNTH
$6.11B
$15.9M 2.93%
162,990
– –
XBI icon
12
PUT
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$15.8M 2.92%
+100,000
New +$13.5M
DGX icon
13
Quest Diagnostics
DGX
$25.9B
$13.8M 2.55%
65,122
+24,305
+60% +$4.77M
IONS icon
14
Ionis Pharmaceuticals
IONS
$9.39B
$11.4M 2.11%
144,376
– –
EYPT icon
15
EyePoint Inc
EYPT
$390M
$11M 2.02%
767,098
– –
ALMS
16
Alumis Inc
ALMS
$1.35B
$7.84M 1.45%
278,546
-46,500
-14% -$1.08M
VKTX icon
17
Viking Therapeutics
VKTX
$3.99B
$7.05M 1.3%
180,731
– –
CELC icon
18
Celcuity
CELC
$4.55B
$6.21M 1.15%
59,316
+43,740
+281% +$5.05M
CYTK icon
19
Cytokinetics
CYTK
$10.3B
$6.02M 1.11%
70,700
+54,400
+334% +$3.91M
MRK icon
20
Merck
MRK
$367B
$6M 1.11%
46,700
– –
RAPP
21
Rapport Therapeutics
RAPP
$2.16B
$5.77M 1.07%
138,508
– –
JNJ icon
22
Johnson & Johnson
JNJ
$648B
$5.74M 1.06%
22,600
– –
GH icon
23
Guardant Health
GH
$22B
$5.72M 1.05%
+38,100
New +$4.14M
ABSI icon
24
Absci
ABSI
$1.52B
$5.38M 0.99%
+464,444
New +$2.62M
SRRK icon
25
Scholar Rock
SRRK
$6.9B
$5.3M 0.98%
96,285
– –
1
2 3

Similar funds

CA
CV Advisors Aventura, Florida $542M AUM 24.89% 1-Year Est. Return
WCM
Westerly Capital Management San Francisco, California $542M AUM 48.48% 1-Year Est. Return
LI
Louisbourg Investments Dieppe, New Brunswick, Canada $542M AUM 21.44% 1-Year Est. Return
CWWM
Clear Wave Wealth Management Red Bank, New Jersey $541M AUM
FVCM
F&V Capital Management Boca Raton, Florida $542M AUM 46.38% 1-Year Est. Return
LI
Lafayette Investments Ashton, Maryland $542M AUM 22.5% 1-Year Est. Return
CCT
Chemung Canal Trust Elmira, New York $541M AUM 32.42% 1-Year Est. Return
MFS
Madrona Financial Services Everett, Washington $543M AUM 30.87% 1-Year Est. Return

Artia Global Partners's Q2 2026 Portfolio in Review

As of Q2 2026, Artia Global Partners held 57 positions worth $542M, up 8.5% from $499M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Artia Global Partners deployed $30.9M of net new capital in Q2 2026, opening 7 new positions and adding to 11 existing holdings. Its largest new stake was Alkermes: 448,964 shares worth $23.5M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 89% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Abivax, an estimated $9.54M trimmed.

  • Artia Global Partners's largest Q2 2026 buy was Alkermes: 448,964 shares worth $23.5M.
  • Artia Global Partners added most to BrightSpring Health Services in Q2 2026, an estimated $25.7M increase.
  • Artia Global Partners's biggest Q2 2026 reduction was Abivax, cutting an estimated $9.54M.
  • Artia Global Partners fully exited Eli Lilly in Q2 2026, selling an estimated $35.2M.
  • Artia Global Partners's ten largest holdings make up 65% of its $542M portfolio in Q2 2026.
  • Artia Global Partners opened 7 new positions and closed 9 in Q2 2026.
  • Artia Global Partners's portfolio value rose 8.5% quarter-over-quarter to $542M.

Based on Artia Global Partners's 13F filing for Q2 2026, filed 14 Aug 2026.